Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus johnsonii la1 + bifidobacterium longum bb536
- Development stage
- Unknown
- Lead developer
- Morinaga Milk Industry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
La1 + BB536 is a probiotic combination consisting of the bacterial strains *Lactobacillus johnsonii* La1 (also known as NCC 533) and *Bifidobacterium longum* BB536. This formulation has been investigated in clinical research, specifically for perioperative administration in patients undergoing surgery for colorectal cancer. The combination aims to modulate the intestinal microbiota by reducing the concentration of pathogenic bacteria, such as Enterobacteriaceae, and enhancing local mucosal immunity. In clinical trials, the La1 strain has demonstrated the ability to adhere to the colonic mucosa, whereas BB536 contributes to the overall probiotic effect without significant mucosal adherence. The treatment is intended to improve surgical outcomes by strengthening the intestinal barrier and regulating inflammatory responses.
- Other names
- Lactobacillus johnsonii La1Bifidobacterium longum BB536Lactobacillus acidophilus La1Lactobacillus johnsonii NCC 533Bifidobacterium longum ATCC BAA-999
Beyond the preview
Go deeper on lactobacillus johnsonii la1 + bifidobacterium longum bb536.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus johnsonii la1 + bifidobacterium longum bb536.